Multiple Endocrine Neoplasia Type 2B Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation.

Abstract

BACKGROUND:

Mixed medullary and follicular thyroid carcinoma (MMFC) displays heterogeneous morphological components and immunophenotypical features intermingled within the same lesion, which is rare and most described in the sporadic form. We report herein a Chinese patient with multiple endocrine neoplasia type 2B (MEN2B) harboring germline RET M918T and associated MMFC.

METHODS:

A case of a 39-year-old male patient with MEN2B presented palpable neck masses in both thyroid lobes (maximum sizes: left, 3.9 cm; right, 5.4 cm) and a definitive phenotype. Serum levels of calcitonin (Ctn; >2000pg/mL), carcinoembryonic antigen (CEA; 719.27ng/mL), and thyroglobulin (Tg; 98.54ng/mL) were high. Fine-needle aspiration cytology showed features positive for malignancy, suggesting the possibility of medullary thyroid carcinoma (MTC). Total thyroidectomy, along with extending bilateral neck lymph nodes dissection, and subsequently, genetics family screening were performed.

RESULTS:

The histopathological examination yielded a diagnosis of MMFC that showed immunohistochemical characteristic patterns of the component of MTC positive for Ctn and CEA, chromogranin A, and the follicular carcinoma components were positive for Tg. Lymph node metastasis was observed showing medullary tumoral cells positive for Ctn and follicular-like structures lacking tumor cells positive for Tg staining (T4bN1bM0). Genetics screening confirmed RET M918T (c.2753T>C) mutation manifested in the patient but was not detected in other family members. Follow up showed that the serum Ctn, CEA and Tg levels respectively dropped to 54.38pg/ml, 4.16ng/mL and 0.04ng/mL 16 months after the surgery.

CONCLUSION:

Particular and diverse patterns of MMFC should be recognized with immunostaining features. MMFC occurring in a patient with MEN2B harboring RET M918T may be unique biological behavior and the treatment is mostly radical surgery.

• Authors: Xiao-Ping Qi, Guo-Bing Lin, Bo Chen, Feng Li, Zhi-Lie Cao, Wei-Hui Zheng, Jian-Qiang Zhao
• Journal: Endocrine, metabolic & immune disorders drug targets (Endocr Metab Immune Disord Drug Targets) Vol. 21 Issue 3 Pg. 554-560 ( 2021) ISSN: 2212-3873 [Electronic] United Arab Emirates
• PMID: 32660411 (Publication Type: Case Reports)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Chemical References

• Biomarkers, Tumor
• Carcinoembryonic Antigen
• MAS1 protein, human
• Proto-Oncogene Mas
• TG protein, human
• Calcitonin
• Thyroglobulin
• Proto-Oncogene Proteins c-ret
• RET protein, human

Topics

• Adenocarcinoma, Follicular (blood, genetics, pathology, surgery)
• Adult
• Biomarkers, Tumor (blood, genetics)
• Calcitonin (blood)
• Carcinoembryonic Antigen (blood)
• Carcinoma, Neuroendocrine (blood, genetics, pathology, surgery)
• Genetic Predisposition to Disease
• Germ-Line Mutation
• Humans
• Male
• Multiple Endocrine Neoplasia Type 2b (blood, genetics, pathology, surgery)
• Phenotype
• Proto-Oncogene Mas
• Proto-Oncogene Proteins c-ret (genetics)
• Thyroglobulin (blood)
• Thyroid Neoplasms (blood, genetics, pathology, surgery)
• Thyroidectomy
• Treatment Outcome